Issue:
108
Page: 8-17
Chamomile
Matricaria
chamomilla (syn.
M. recutita, Chamomilla recutita)
Family: Asteraceae
by Gayle Engels, Josef Brinckmann
HerbalGram.
2015; American Botanical Council
INTRODUCTION
Chamomile, also called German or
Hungarian chamomile, is known by the Latin binomial Matricaria
chamomilla,
although the synonyms M. recutita and Chamomilla recutita are
still used by some.1 The common name chamomile and specific name chamomilla come from the Greek chamos, meaning ground, and melos, meaning apple, which refers to the
plant’s low-growing habit and apple-like scent.2 The generic name, Matricaria, comes from the Latin matrix, meaning womb, because it was used
historically to treat disorders of the female reproductive system.3
Growing up to 30 inches (76 cm) in
height, chamomile is an herbaceous annual plant with ferny, fragrant leaves. It
has heterogamous (having multiple sexes) inflorescences with tubular yellow
disc florets surrounded by white ray flowers.3,4 The brownish-yellow
fruit, or achene, contains a single seed that does not split open upon drying.
Chamomile is native to eastern and
southern Europe as well as parts of western Asia, and now occurs throughout
almost all of Europe as well as Turkey, the Caucasus region (Georgia), and
parts of Iran and Afghanistan. The material of commerce is obtained, for the
most part, from farms in Egypt, Germany, Argentina, Poland, and, to a lesser
extent, Chile, the Czech Republic, Slovakia, Spain, and several of the Balkan
countries (Bosnia and Herzegovina, Bulgaria, Croatia, and Serbia).5
It is also wild-collected for commercial trade in Hungary,6 as well
as in Albania, Bulgaria, Croatia,7 Kosovo,8 and
Macedonia.9
This article addresses only M.
chamomilla and not
the many other herbs also referred to in commerce as chamomile, such as English
or Roman chamomile (Chamaemelum nobile, syn. Anthemis nobilis), corn
chamomile (A.
arvensis), dyer’s
chamomile (Cota
tinctoria), Moroccan chamomile (Cladanthus mixtus), Moroccan blue chamomile (Tanacetum annuum),
rayless chamomile (M. discoidea), and scentless chamomile (Tripleurospermum
perforatum), all of
which belong to the family Asteraceae.10,11 Although chamomile and
Roman chamomile have been used interchangeably, their growth habits and
essential oils are vastly different.3
Roman chamomile sometimes causes
allergic reactions in individuals who are sensitive to ragweed (Ambrosia
artemisiifolia, Asteraceae), which rarely occur with M.
chamomilla.3,12
However, the World Health Organization (WHO) contraindicated chamomile use in
people with known sensitivities to plants in the Asteraceae family.13
Proper identification of plant material is imperative to avoid allergic
reactions. In one notable instance, a voucher specimen was misidentified as
chamomile but was, in fact, dog’s chamomile (Anthemis cotula, Asteraceae), which is highly allergenic
due to its anthecotulid content.14
HISTORY AND CULTURAL SIGNIFICANCE
Ancient Egyptian, Greek, and Roman
medicine texts contain descriptions of using chamomile as a calming tisane
(herbal tea infusion) and for treating erythema (superficial reddening of the
skin) and xerosis (abnormally dry skin) caused by dry weather.12
Both the Egyptians and Saxons held chamomile sacred, and, in Slovakia, a person
was supposed to bow to chamomile plants when he or she encountered them.
Chamomile is found in the writings of early Greek botanists/physicians
Hippocrates (5th century BCE) and Dioscorides (1st century CE), and the Roman
physician Galen (2nd century CE).2 By the 16th and 17th centuries,
chamomile was used extensively for intermittent fever.12
The Unani system of medicine, which
is practiced on the Indian subcontinent, uses chamomile (called Gul-e-Babuna)
by itself or in combination with other herbs for the following conditions:
headache, gonorrhea, conjunctivitis, chest pain, renal calculi (kidney stones),
vesical calculi (bladder stones), general debility, hysteria, dyspepsia, and
fever.15
Chamomile was first cultivated in
the United States by German settlers and became an important medicine employed
by 19th century American Eclectic physicians, who used it specifically for
conditions in pregnant women and young children.2,16 Traditionally,
chamomile flower extracts have been used internally for the following: nervous
system conditions (e.g., restlessness and anxiety), depression, insomnia,
flatulence, indigestion, constipation, diarrhea, hemorrhoids, amenorrhea
(abnormal absence of menstruation), dysmenorrhea (painful menstruation),
anorexia nervosa, asthma, bruxism (teeth grinding), bronchitis, colic,
dentition and infantile convulsions caused by teething, gout, gum bleeding and
soreness, canker sores (ulcers), malaria, travel sickness, alcohol withdrawal,
mastitis (breast inflammation or infection), neuralgia, skin irritations,
eczema, bruises, burns, and wounds.12,16,17
Externally, chamomile extracts have been
used to address cracked nipples, chicken pox, diaper rash, eye conditions
(e.g., blocked tear ducts and conjunctivitis), ear infections, nasal
conditions, and poison ivy reactions.17 They also have been used in
cosmetics and body care products such as hair dyes, shampoos, sunscreens,
mouthwashes, toothpastes, deodorants, and bath preparations.18
Chamomile essential oil has been included as an ingredient in creams, lotions,
perfumes, soaps, and detergents.
Germany has always been a major
producer and consumer of German/Hungarian chamomile. The herb enjoys relatively
widespread use and cultural acceptance in the country. (In addition to its
German name Kamillenblüten, it is also known there as alles zutraut, which means “capable of anything.”) Between 1930
and 1945, Germany’s average annual demand was about 1,000 metric tons (MT),
most of which was wild-collected with only six hectares (ha) being cultivated.5
And as late as 1955, Germany was still its own main source of chamomile (mainly
from the state of Saxony and the Franconia region of Bavaria) followed by
imports from Hungary, the Balkan countries, the former Soviet Union,
Czechoslovakia, and Yugoslavia, among others.
In the 1950s, an estimated 40-50% of
world demand could be satisfied with wild-collected chamomile from Hungary.6
But, in the 1990s, lower-cost production of cultivated chamomile, particularly
in Egypt and Argentina, scaled up and eventually ruined the market for wild
Hungarian chamomile.
In 1984, the German Commission E
approved the use of chamomile flower preparations as internal nonprescription
medicines for gastrointestinal spasms and inflammatory diseases of the
gastrointestinal tract, and as external medicines for skin and mucous membrane
inflammation, bacterial skin diseases (including those of the oral cavity and
gums), and inflammation or irritation of the respiratory and anogenital tracts.
The British Herbal Compendium lists chamomile for internal use for
spasms or inflammatory conditions of the gastrointestinal tract, peptic ulcers,
and mild sleep disorders, and for external use for eczema, inflammation, and
irritation of skin or mucosa.2
CURRENT AUTHORIZED USES IN COSMETICS, FOODS, AND MEDICINES
In 1982, the US Food and Drug
Administration (FDA) considered the inclusion of chamomile flower as an active
ingredient in its establishment of a monograph for over-the-counter (OTC)
digestive aids.19 But, in 1993, due to an insufficient amount of
human clinical evidence submitted to the FDA, the agency ruled that chamomile
flower was not generally recognized as safe and effective (GRASE) for use as a
digestive aid active ingredient.20
However, in 2000, the FDA ruled that
some OTC drug monograph claims would now be acceptable as structure/function
claims for certain dietary supplement products.21 At that point, it
became clear that chamomile flower could be labeled and marketed as a dietary
supplement with “digestive
aid,” “relief of
occasional indigestion,” or similar claims, so long as the product’s marketer
had fulfilled all of the regulatory requirements for the manufacture and
marketing of dietary supplements (e.g., substantiation of claim[s], submission
of FDA notification letter within 30 days of marketing, etc.).
For use of chamomile flower as an
ingredient with an associated structure/function claim, the United States
Pharmacopeia (USP) has established a quality standards monograph (for dried
flower heads) that can serve as the basis of a company’s specifications for
verifying composition, identity, quality, purity, and strength.22
For use in conventional food
products, the FDA has determined that (German/Hungarian) chamomile flower is
generally recognized as safe (GRAS) for use as a spice, natural seasoning, or
flavoring.23 Furthermore, the FDA classifies essential oils,
solvent-free oleoresins, and natural extracts (including distillates) of
chamomile as GRAS for use in food products.24 The Food Chemicals
Codex (FCC) includes a quality standards monograph for “German
Type Chamomile Oil” for
use as a food flavoring agent. The monograph is available from USP.25
In Canada, German chamomile is
regulated as an active ingredient of licensed natural health products (NHPs),
requiring pre-marketing authorization from the Natural and Non-prescription
Health Products Directorate (NNHPD).26 The authorized uses for
labeling of German chamomile NHPs vary depending on buccal, oral, or topical
application:
Buccal: “to help relieve minor inflammation
and/or irritation of the mucous membranes of the mouth and/or throat”;
Oral: (1) “to help relieve inflammatory
conditions of the gastrointestinal tract”; (2) “to help relieve mild digestive
disturbances (such as dyspepsia, flatulence, bloating, and/or belching)”; (3) “as a calmative and/or sleep aid”;
and
Topical: “to help relieve minor inflammation
and/or irritation of the skin.”
German chamomile is also listed in
the NNHPD draft “Cognitive
Function Products” monograph as a sedative active ingredient.27
German chamomile essential oil is listed in the draft “Aromatherapy – Essential Oils” monograph
with the following proposed claim statements:
Topical: (1) “for symptomatic relief of acne/boils”;
(2) “to relieve minor
skin irritation/cuts/bruises/burns”; and
Topical and/or inhalation: (1) “as a
nervine/calmative”; (2)
“to help relieve
joint/muscle pain associated with sprain/strain/rheumatoid arthritis”; (3) “to help relieve headache”; and (4) “as a carminative/antispasmodic for
symptomatic relief of digestive discomfort.”28
At the time of this writing
(September 2015), there were 960 chamomile-containing licensed NHPs in Canada
(521 listed as Matricaria chamomilla, 329 as Matricaria recutita, and 110 as chamomile), of which
723 product licenses list chamomile, in some form, as a medicinally active
ingredient.29 German chamomile flower water is allowed as a
non-medicinal fragrance ingredient of topical NHPs. The essential oil is also
allowed as a non-medicinal fragrance ingredient and skin-conditioning agent.
In the European Union (EU), various
defined chamomile preparations — in particular, herbal tea infusions (for oral
ingestion, oromucosal use [gargle and rinse], topical application [dressings
and washes], and steam inhalation), essential oils, and varying strengths of
dry and liquid extracts — are regulated as traditional herbal medicinal
products (THMPs), requiring registration and pre-marketing authorization.30
Therapeutic indications for the herbal tea, dry extract, and liquid extract
forms include:
Oral: “for the symptomatic treatment of
minor gastrointestinal complaints such as bloating and minor spasms”;
Steam inhalation: “for the relief of symptoms of common
cold”;
Oromucosal:
“for the treatment
of minor ulcers and inflammations of the mouth and throat”;
Cutaneous
(sitz bath): “for
adjuvant therapy of irritations of skin and mucosae in the anal and genital
region, after serious conditions have been excluded by a medical doctor”; and
Cutaneous (dressings and washes): “for the treatment of minor
inflammation of the skin (sunburn) and superficial wounds and small boils (furuncles).”
The therapeutic indications for the
essential oil are the same as those for the above-listed cutaneous use (sitz
bath).31
For quality control, applicants must
show that the herbal drug or preparation complies with a quality standards
monograph of the European Pharmacopoeia (i.e.,“Matricaria Flower,” “Matricaria
Liquid Extract,” or “Matricaria
Oil”) and the relevant
corresponding general monographs, such as “Essential Oils,” “Herbal Drug Extracts,” “Herbal
Teas,” and “Herbal
Preparations.”32
There are two distinct European
chamomiles with “Protected
Designation of Origin” (PDO) standards under EU regulations: Alföldi kamillavirágzat (“Wild Alföld Chamomile”) from Hungary and Chamomilla
Bohemica (“Bohemian Chamomile”) from the Czech
Republic.
The Alföldi kamillavirágzat PDO standard requires that it is
hand-picked using a chamomile comb (made from wood, iron, or tin) from the
saline soils of the Great Hungarian Plain (specifically in the counties of
Szabolcs-Szatmár-Bereg, Borsod-Abaúj-Zemplén, Heves, Jász-Nagykun-Szolnok, Hajdú-Bihar, Békés, Csongrád, Bács-Kiskun, and Pest). The unique
characteristics of this low-growing wild chamomile are attributed to the
traditional methods of harvesting and processing and the area’s ecological
features, including saline soil, high temperatures, abundant sunshine
(approximately 2,000 hours/year), and low annual precipitation (500-600 mm, or
about 20-24 inches).33
When harvested, dried, and handled
according to the PDO specifications, the herb’s quality should, at a minimum,
conform to the requirements of the Hungarian Pharmacopoeia. Depending on the
year, the alpha-bisabolol content of the essential oil fraction should be at
least 20%, and possibly as high as 58%, which is significantly higher than the
norm for cultivated chamomile of any origin.34 The Alföldi kamillavirágzat PDO standard correlates its high
alpha-bisabolol content with antispasmodic, anti-inflammatory, and
anti-ulcerative effects.
The Chamomilla
Bohemica PDO
standard requires the plant to be grown in Bohemia (including the regions of
Prague, Central Bohemia, South Bohemia, Plzeň, Karlovy Vary, Ústí nad Labem,
Liberec, Hrádec Králové,
Pardubice, and Vysočina, as well as the districts of Havlíčkův Brod, Jihlava,
and Pelhřimov).35 The unique characteristics of this chamomile are
attributed to a combination of factors such as climate (altitude, plentiful
sunshine, and average rainfall of 500-700 mm, or about 20-28 inches), soil (pH
of 7.3-8.1 and loamy/sandy-type), and traditional harvesting methods.
When harvested, dried, and handled
according to the PDO specifications, Chamomilla Bohemica should have a blue essential oil
content of up to 1%, which is 2.5 times the minimum requirement of the Czech
Pharmacopoeia (min. 0.4%).34 Furthermore, the chamazulene content must average
0.06-0.07%, or about twice the pharmacopeial minimum level of 0.035%. The Chamomilla
Bohemica PDO
standard also correlates its flavonoid content (about 0.015%) with spasmolytic
effects and its spiroether content (0.03%) with bacteriostatic and fungicidal
effects.
Besides the Czech and Hungarian
national pharmacopeias and PDO specifications, there are English-language
quality standards monographs for various forms of chamomile published in the
European Pharmacopoeia (“Matricaria Flower,” “Matricaria Liquid Extract,” and “Matricaria
Oil”),32 Food
Chemicals Codex (“German Type Chamomile Oil”),25 International
Organization for Standardization (ISO) standards (“Oil of Blue Chamomile”),36
and the United States Pharmacopeia (“Chamomile [dried flower heads]”),22
as well as in WHO Monographs on Selected Medicinal Plants (“Flos
Chamomillae”).13
MODERN RESEARCH
In pharmacological and animal
studies, chamomile extracts have exhibited the following properties: anti-anxiety
and stress relieving, anticancer, anti-inflammatory, anti-insomnia,
antioxidant, antimutagenic, antinociceptive (reducing sensitivity to pain),
antipeptic, antispasmodic, antistaphylococcal, anti-ulcerative, anti-itch,
cytotoxic, immunomodulating, hepatoprotective, neuroprotective,
skin-metabolizing, stress-relieving, and wound-healing.2,12,15,16
Chamomile essential oil and its constituents have demonstrated antispasmodic,
anti-inflammatory, antimicrobial, antiedemic, antipeptic, anxiolytic, bactericidal,
chemopreventive, fungicidal, and wound-healing properties.15
In 1985, a controlled, bilateral,
comparative study investigated the effects of chamomile cream on inflammatory
dermatoses.37 Patients (N = 161) who had previously been treated
with 0.1% difluocortolone valerate were given one of four preparations to apply
for three to four weeks: Kamillosan® cream (a dry extract of
chamomile flowers [2.75:1, ethanol 95.4% (v/v)] in a fatty ointment base
containing no less than 0.2 mg volatile oil and no less than 0.07 mg
(-)-a-bisabolol; VIATRIS GmbH & Co; Frankfurt, Germany), 0.25%
hydrocortisone, 0.75% fluocortin butyl ester, or 5% bufexamac. Kamillosan was
as effective as hydrocortisone and superior to fluocortin butyl ester and
bufexamac in treating inflammatory dermatoses. Additionally, Kamillosan was
comparable to hydrocortisone and superior to other tested products in treating
neurodermatitis.
A 2009 randomized, double-blind,
placebo-controlled study investigated the efficacy of chamomile extract on
generalized anxiety disorder (GAD).38 Over an eight-week period, 57
patients with mild-to-moderate GAD took either chamomile extract (n = 20)
standardized to 1.2% apigenin (Spectrum Pharmacy Products; New Brunswick, New
Jersey) or placebo (n = 29) at the rate of one 22 mg capsule per day for the
first week, increasing one capsule per day for each week through week four.
Patients with a 50% reduction in symptoms or less were increased to five
capsules daily for weeks five through eight of therapy. Symptoms were measured
at baseline and after two, four, six, and eight weeks of treatment. A
statistically significant superiority in anxiety test scores (P = 0.047,
Hamilton Anxiety Rating, or HAM-A) was seen in the chamomile group compared to
placebo.
Using data from the previous study,
Amsterdam et al. investigated whether the chamomile extract also treated
depression.39 Of the 57 participants in the 2009 study, 19 had
anxiety with depression, 16 had anxiety with a history of depression, and 22
had anxiety with no history of depression. Researchers analyzed the Hamilton
Depression Rating (HAM-D) questionnaire completed by participants (before,
during, and after treatment) and discovered significantly greater reductions in
scores over time for the chamomile group versus the placebo group (P
< 0.05), and a meaningful but nonsignificant reduction in participants with
current depression (P = 0.062).
A randomized, pre-post study
performed in 2009-2010 investigated the efficacy of chamomile in treating
irritable bowel syndrome (IBS). Patients diagnosed with IBS (N = 45) took 20
drops per day of a chamomile extract (69.47 mg/100 mL bisabolol and
chamazulene; SohaJissa Company; Tehran, Iran) for four weeks.40
Patients filled out a questionnaire on day one, at weeks two and four, and two
and four weeks after the end of the intervention. Symptoms were significantly
reduced at weeks two and four (P = 0.001), and relief from symptoms
continued up to two weeks after the intervention ended.
A few studies have assessed the
usefulness of chamomile in treating stomatitis, a painful inflammation of the
oral mucosa that can include ulceration. In two experiments, chamomile was
found to be as effective as the conventional pharmaceutical comparison drugs
(allopurinol mouthwash vs. chamomile mouthwash,41 and triamcinolone
in Orabase® vs. chamomile in Orabase,42 respectively). In the first study,
the allopurinol and chamomile mouthwashes were equally effective in reducing
stomatitis in chemotherapy patients, but the authors noted that the lower cost
and greater availability of chamomile (i.e., it does not require a
physician’s prescription) may make it a better choice for some patients. In the
second study, while chamomile did not resolve all symptoms as rapidly as the
conventional pharmaceutical drug triamcinolone, pain intensity reduction and
patient satisfaction scores were similar between groups.
In a third study, chamomile
mouthwash was more effective in treating recurrent aphthous stomatitis (RAS;
canker sores) than placebo.43 In this triple-blind study, 50
patients with aphthous lesions were randomized to receive either chamomile
tincture (amount not specified; Matrica Drop; Iran Darouk, formerly Barij
Essence; Tehran, Iran) or placebo. Patients were instructed to apply 10 drops
three times per day, rinse for three minutes, expectorate, and refrain from
eating for 30 minutes. Patients were examined after two, four, and six days,
then weekly. The changes in the chamomile group — fewer number of lesions (P
= 0.025), smaller lesion size (P = 0.03), and less pain and burning
sensation (P = 0.001) — were statistically significant at each
examination compared to the placebo group.
In a 2015 study that investigated
the efficacy of chamomile in treating knee osteoarthritis (OA), 84 patients with
OA were randomized to three groups and instructed to apply their assigned
medication to the knee and surrounding area three times per day for three
weeks.44 One group applied 1.5 mL chamomile oil (prepared at Shiraz
University in Iran by traditional direct-heat extraction*); the second group
applied diclofenac gel; and the control group applied paraffin. Patients were
allowed to take 500 mg acetaminophen as needed, and use of the analgesic was
examined as one of the outcome measures, along with a self-administered Western
Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire at
the beginning of the study and every week during the study. The number of
acetaminophen tablets taken by the chamomile group was significantly lower than
those taken by the other two groups, and, while the chamomile oil showed some
beneficial effects on pain, stiffness, and physical activity, these effects did
not differ significantly different from the other two groups. The authors
recommended further research with larger study populations.
A 2014 prospective, randomized,
double-blind study compared chamomile extract to mefenamic acid (MA; a
non-steroidal anti-inflammatory drug [NSAID] used to treat pain) for reducing
the intensity of mastalgia (breast pain) associated with premenstrual syndrome.45
Ninety female university students were randomized to receive either 100 mg
chamomile (capsules prepared from plant material purchased from Zarband;
Tehran, Iran; no further information supplied) or 250 mg MA three times per day
from the 21st day of their menstrual cycle until onset for six months. Both
chamomile and MA relieved mastalgia intensity with no significant difference
between the groups. The authors recommended further studies that do not rely on
data collection through subject self-reporting.
In a randomized, double-blind,
placebo-controlled pilot study published in 2015, chamomile oil obtained
through traditional direct-heat method was investigated for its efficacy in
treating severe carpal tunnel syndrome (sCTS) when applied topically as a
complementary therapy.46 Twenty-six patients with documented sCTS
were randomized to apply chamomile oil or placebo (paraffin, sesame oil, and 1%
chamomile essential oil to mimic the aroma of the chamomile oil) twice daily
for four weeks, in addition to wearing an immobilizing wrist splint at night.
Primary and secondary outcomes were measured at enrollment and after four
weeks. The patients in the chamomile oil group showed significant improvements
in severity of symptoms (P = 0.019) and functional ability (P =
0.016) compared to placebo.
Chamomile performed well in a 2011
controlled study comparing its efficacy in managing peristomal skin lesions in
colostomy patients versus treatment with hydrocortisone ointment.47
Participants were assigned to the chamomile group (n = 36) or control group (n
= 36) based on matching demographics, history, and skin-condition variables.
Patients in the experimental group applied a chamomile compress (6 g air-dried
and powdered flower heads steeped in 150 mL boiled water for 10 minutes,
strained, and applied to gauze) to the wound for one hour once per day. The
control group applied 1% hydrocortisone ointment to their wound once per day.
Lesions were evaluated every three days for 28 days, and healing occurred
significantly faster in the chamomile group than in the hydrocortisone group
(8.89 ± 4.89 days versus 14.53 ± 7.6 days, respectively). Additionally, pain
and itching around the stoma was relieved more quickly in the chamomile group.
A 2005 controlled, double-blind,
crossover study investigated a chamomile mouthwash for its ability to reduce
dental plaque and gingival inflammation.48 For two four-week periods
separated by a washout period of two weeks, 25 randomly assigned patients with
gingivitis rinsed with either a chamomile mouthwash (air-dried and powdered
chamomile flowers percolated at room temperature with 55% ethanol, extracts
filtered, evaporated under vacuum at low temperature, dried residue suspended
in water) or control (solvent with no other ingredients). Both groups were
instructed to dilute 20 drops of mouthwash with 20 mL water and rinse twice a
day for two minutes, once before bedtime. Plaque, gingival inflammation, and
stain indices were recorded at baseline and measured at the end of each
experimental period and the end of the washout period. Mean reduction for
plaque (22 ± 17.83 vs. 5.4 ± 7.93) and gingival indices (0.31 ± 0.23 vs. 0.03 ±
0.11) were significantly greater for the chamomile mouthwash than for the
control. Also, there was no significant staining or reduction in baseline
staining in the chamomile group.
A prospective epidemiological study
published in 2015 explored the connection between chamomile tea consumption and
all-cause mortality over the course of seven years in a sample of older
Mexican-Americans in the southwestern United States.49 Of the
sample, 13.95% consumed chamomile. Per the Kaplan-Meier estimator, chamomile
consumers showed increased overall survival (P = 0.008), with women
consumers demonstrating even greater survival (P = 0.011). In the Cox
proportional hazards model for all-cause mortality, chamomile was linked to a
29% reduction in mortality risk for the entire sample, a 33% reduction in risk
for women, and a nonsignificant reduction for men.
In a 2015 age- and gender-matched
case-control study, chamomile tea consumption was associated with a reduction
in both benign and malignant thyroid diseases (P < 0.001).50
The odds of developing any type of thyroid disease decreased significantly with
increased frequency of chamomile consumption. Additionally, the risk of
developing benign thyroid diseases or thyroid cancer was significantly reduced
in those who had consumed chamomile tea for 30 or more years.
FUTURE OUTLOOK
Today, the most important chamomile
cultivation areas in Germany are in the states of Thuringia, Bavaria, Saxony,
Saxony-Anhalt, and Lower Saxony.51 Chamomile ranks as Germany’s
third most popular herbal tea in terms of volume purchased, with an overall
2014 demand of 4,095 MT.52
Annual global trade volume for
chamomile flower has been estimated to be up to 8,000 MT, mainly supplied by
farms in Egypt, Germany, Poland, Argentina, and Slovakia.5 The area
of farmland dedicated to chamomile cultivation is approximately 1,500 ha in
Egypt and 1,200 ha in Germany (1,000 ha of which are in the state of
Thuringia).5 Poland has an estimated 750 ha of chamomile
cultivation.53 Other countries that produce and consume significant
amounts of chamomile are not included in external trade data. For example, Iran
has an estimated 1,000 ha of chamomile production.5
While Egypt is the world’s top
producer and exporter of chamomile, Germany is the top importer. According to
El-Shrief et al., Egypt exported an average of 2,592 MT of chamomile annually
between 1996 and 2008. Germany imported an average of 1,025 MT (39.5%) followed
by 391 MT imported by Spain (15.1%), 202.6 MT by the United States (7.8%), 185
MT by Italy (7.1%), and 131.5 MT by the Netherlands (5.1%).54
However, a market study funded by the German Ministry for Economic Cooperation
and Development (BMZ) found that Egypt’s annual export of chamomile was
significantly higher, at 5,878 MT, of which 4,013 MT (68.3%) was imported by
member states of the EU (mainly Germany, Poland, and the Netherlands), followed
by the United States (405 MT; 6.9%), Venezuela (365 MT; 6.2%), and Russia (234
MT; 3.9%).55 On average, Germany’s annual demand accounts for more
than half the estimated global d emand, at about 4,500 MT, of which about 600
MT are produced domestically and about 3,900 MT are imported.56
There are several quality grades of
chamomile, each playing a distinct role in the market:
• Chamomile flower (Matricariae flos)
is of pharmacopeial quality and consists of the capitula (infloresence)
separated from leaf and stem. It is used in medicinal teas, tinctures, and
other phytomedicinal preparations;
• Chamomile fines (Camomile fines) is
what is left after removing the capitula. If the essential oil content is high
enough, it may be used in pharmaceutical preparations; otherwise, it is used in
food products;
• Chamomile herb with flowers
(Chamomillae cum floribus herba) is machine-harvested with a high stem content.
This material does not conform to pharmacopeial standards and is used in food
products or non-medicinal beverage teas; and
• Chamomile herb (Chamomillae herba)
is not produced by plucking the flowers, but rather by cutting the entire
aerial parts and without further post-harvest sorting or separating. Due to the
high content of plant parts other than the flower heads, this material is used
primarily to make extracts for the cosmetics industry.5
There are other lower-quality grades
as well. One of the authors of this article (JB) has observed the blending of
inferior grades destined for the low-price beverage tea market, comprised
mainly of chamomile herb (stems and leaves) after the flowers have been mostly
sifted out, with as much as 25% chamomile seed admixed.
For reasons including quality
assurance, safety, and traceability, there has been a resurgence of interest in
the cultivation of medicinally and economically important herb crops in Europe,
especially chamomile. A 2014 market analysis determined that at least 7,200 ha
of chamomile cropland in Germany would be necessary for the country to produce
100% of its herbal industry's demand. Presently, Germany produces roughly 16%
of its annual chamomile demand.57
Cultivation of chamomile is also
increasing in other European countries. For example, there is an ongoing US
Agency for International Development (USAID) project in Kosovo to support the
development of cultivated medicinal and aromatic plant crops for its export
market. More than 60% of the acreage in this project is dedicated to chamomile.58 Chamomile cultivation in
neighboring Serbia is also increasing with an estimated 250 ha in 2013.59
Serbia is home to Euro Prima, one of
the world’s leading producers and suppliers of harvest and post-harvest
machines specifically designed for German chamomile crops.60 Because
pharmacopeial-quality chamomile is composed of only the capitula, specialized
equipment is needed when machine-harvesting the entire aerial parts in order to
effectively separate the inflorescence from the stalks before drying.
If they are not picking flowers
manually, most chamomile farmers around the world are still using mechanical
harvesters developed in the mid-1970s. Until recently, very little research has
been conducted to improve the technology. A four-year study from 2010-2013
funded by the German Federal Ministry of Food, Agriculture and Consumer
Protection (BMELV) evaluated current methods and equipment used for mechanical
harvesting of chamomile with the goal to develop a modernized harvesting
machine for improved efficiency and quality.61-63 A related one-year
German government-funded project in 2014-2015 aimed to optimize the newly
developed chamomile flower harvester in order to finalize the design of a
production-ready prototype.64
Chamomile flower remains one of the
most in-demand medicinal plants in global trade, and annual demand predictably
will continue to grow. Up until the mid-20th century, market requirements were
satisfied by wild collection in eastern and central Europe — particularly in
Germany, Hungary, and the Balkan countries — but, in recent decades, cultivation
has scaled up in certain African and South American countries (e.g., Egypt and
Argentina, respectively) where production costs are lower.
In the 21st century, increasing
demand for sustainable (organic and fair trade) chamomile has become a new factor
for producers to consider.65 While still considered a niche market,
dual-certified “organic
and fair trade” herbs, particularly chamomile, have been showing triple-digit
growth rates.
While certified organic,
wild-collected chamomile is available from Albania, Hungary, and Macedonia, and
certified organic and fair trade cultivated chamomile is available mainly from
Egypt, market demand has consistently exceeded supply in the past few years.
Producers in several countries are working to increase production of organic
and fair trade chamomile to catch up with demand. The trend of sustainable
chamomile production in developing countries in Africa, Asia, and South America
is expected to continue, as is the concurrent trend to increase sustainable
chamomile production (both cultivated and wild) in areas within the herb’s
geographical origin in Europe and western Asia.
—Gayle Engels and Josef Brinckmann
REFERENCES
- Applequist W. The
Identification of Medicinal Plants: A Handbook of the Morphology of Botanicals
in Commerce.Austin, TX: American Botanical Council; 2006.
- Blumenthal M, Goldberg A, Brinckmann J, eds. Herbal Medicine: Expanded
Commission E Monographs. Austin,
TX: American Botanical Council; Newton, MA: Integrative Medicine
Communications; 2000.
- Tucker AO, Debaggio T. The
Encyclopedia of Herbs: A Comprehensive Reference to Herbs of Flavor and
Fragrance. Portland, OR: Timber Press; 2009.
- Singh O,
Khanam Z, Misra N, Srivastava MK. Chamomile (Matricaria chamomilla L.): an
overview. Pharmacogn Rev.January-June
2011;5(9):82-95.
- Franke R, Hannig HJ. Kamille (Matricaria
recutita L.). In:
Hoppe B, et al. Handbuch des Arznei- und Gewürzpflanzenbaus,
Band 4. Bernburg, Germany: Verein für Arznei- und Gewürzpflanzen SALUPLANTA e.V. 2012;618-648.
- Gosztola
B. Doctoral thesis: Morphological and chemical diversity of different chamomile
(Matricaria recutita L.)
populations of the Great Hungarian Plain. Budapest: University of Budapest.
2012.
- Kathe W,
Honnef S, Heym A. Medicinal and
Aromatic Plants in Albania, Bosnia-Herzegovina, Bulgaria, Croatia and Romania.
Bonn, Germany: German Federal Agency for Nature Conservation; 2003.
- Primavera
A. Products, calendar, map of the herbs value chain in Dragash (Kosovo). Rome:
International Link and Services for Local Economic Development Agencies. August
13, 2013.
- Brinckmann
JA, Huggins K, Gardner ZE. Managing natural resources for sustainable
livelihoods: threats to the future of sustainable wild collection and field
experience with implementation of the FairWild standard for medicinal plants.International
Journal on Biodiversity Watch. 2014;3:13-29.
- The Plant
List (2013). Version 1.1. Available at: www.theplantlist.org/. Accessed August
22, 2015.
- USDA
Germplasm Resources Information Network (GRIN). Available at:
www.ars-grin.gov/cgi-bin/npgs/html/tax_search.pl?language=en. Accessed August
22, 2015.
- Das M. Chamomile: Medicinal, Biochemical, and Agricultural
Aspects. Boca
Raton, FL: CRC Press; 2015.
- World
Health Organization (WHO). WHO
Monographs on Selected Medicinal Plants. Vol. 1. Geneva, Switzerland: World
Health Organization; 1999;86-94.
- Awang
DVC. Regulating herbal products: an historical Canadian perspective. HerbalGram. 2010;89:52-54.
- Unani
Pharmacopoeia Committee. Gul-e-Babuna (flower). In: The
Unani Pharmacopoeia of India. Part 1. Vol 2. New Delhi,
India: Government of India, Ministry of Health and Family Welfare, Department
of Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homoeopathy (AYUSH).
2007;39-40.
- Mills S,
Bone K. Principles and Practice of
Phytotherapy: Modern Herbal Medicine. Edinburgh:
Churchill Livingstone; 2000.
- Srivastava
JK, Shankar E, Gupta S. Chamomile: a herbal medicine of the past with a bright
future (review) [published online September 27, 2010]. Molecular Medicine Reports. 2010;3:895-901. doi:10.3892/mmr.2010.377.
- Khan IA,
Abourashed EA. Leung’s Encyclopedia of Common Natural
Ingredients. 3rd ed. Hoboken, NJ: John Wiley and Sons, Inc.; 2010.
- Food and
Drug Administration. 21 CFR Part 357: Digestive aid drug products for
over-the-counter human use; establishment of a monograph. Federal Register. January 5,
1982;47(2):454-487.
- Food and
Drug Administration. 21 CFR Part 310. Status of certain additional
over-the-counter drug category II and III active ingredients; final rule. Federal Register. May 10,
1993;58(88):27443-27650.
- Food and
Drug Administration. 21 CFR Part 101: Regulations on statements made for
dietary supplements concerning the effect of the product on the structure or
function of the body; final rule. Federal
Register. January 6, 2000;65(4):1000-1050.
- United States
Pharmacopeial Convention. Chamomile. United States Pharmacopeia, Thirty-Eighth Revision (USP 38). Rockville, MD: United States Pharmacopeial
Convention. 2015;5955-5958.
- Food and
Drug Administration. § 182.10 Spices and other natural seasonings and
flavorings. In: Code of Federal
Regulations, Title 21 (21 CFR). Washington DC: US Government Printing
Office. 2015;474-475.
- Food and
Drug Administration. § 182.20 Essential oils, oleoresins (solvent-free), and
natural extractives (including distillates). In: Code of Federal Regulations, Title
21 (21 CFR). Washington DC: US Government Printing Office. 2015;475-477.
- United
States Pharmacopeial Convention. Chamomile oil, German type. In: Food Chemicals Codex, Ninth Edition (FCC 9). Rockville, MD: United States Pharmacopeial
Convention. 2015.
- Natural
and Non-prescription Health Products Directorate (NNHPD). German chamomile.
Ottawa, ON: Health Canada. July 31, 2009. Available at:
http://webprod.hc-sc.gc.ca/nhpid-bdipsn/dbImages/mono_chamomile-german--buccal_english.pdf.
Accessed August 22, 2015.
- Natural
and Non-prescription Health Products Directorate (NNHPD). Monograph: cognitive
function products. Ottawa, ON: Health Canada. May 21, 2014. Available at:
http://webprod.hc-sc.gc.ca/nhpid-bdipsn/dbImages/mono_cognitive-function-products-under-consultation_english.pdf.
Accessed August 22, 2015.
- Natural
and Non-prescription Health Products Directorate (NNHPD). Monograph:
aromatherapy – essential oils. Ottawa, ON: Health Canada. October 7, 2014.
Available at:
http://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq.do?atid=aromatherap&lang=eng.
Accessed August 22, 2015.
- Natural
and Non-prescription Health Products Directorate (NNHPD). Licensed natural
health products database. Available at:
http://webprod5.hc-sc.gc.ca/lnhpd-bdpsnh/index-eng.jsp. Accessed: August 22,
2015.
- European
Medicines Agency (EMA) Committee on Herbal Medicinal Products (HMPC) [draft].
Community herbal monograph on Matricaria
recutita L., flos. London, UK:
EMA. July 1, 2014.
- European
Medicines Agency (EMA) Committee on Herbal Medicinal Products (HMPC) [draft].
Community herbal monograph on Matricaria
recutita L., aetheroleum. London,
UK: EMA. July 1, 2014.
- European Pharmacopoeia Commission. European Pharmacopoeia, Eighth
Edition (PhEur
8.0). Strasbourg, France: European Directorate for the Quality of Medicines.
2014.
- European
Commission. Commission implementing regulation (EU) No 165/2012 of 24 February
2012 entering a name in the register of protected designations of origin and
protected geographical indications (Alföldi
kamillavirágzat (PDO)). Official Journal of the European
Union. 2012;55:4-9. Available at:
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:053:0004:0009:EN:PDF.
Accessed August 22, 2015.
- Brinckmann
JA. Emerging importance of geographical indications and designations of origin
— authenticating geo-authentic botanicals and implications for phytotherapy. Phytotherapy Research.
2013;27(11):1581-1587.
- European
Commission. Publication of an application pursuant to Article 6(2) of Council
Regulation (EC) No 510/2006 on the protection of geographical indications and
designations of origin for agricultural products and foodstuffs.Official
Journal of the European Union. 2007;50(C 243):11-13. Available at:
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2007:243:0011:0013:EN:PDF.
Accessed August 22, 2015.
- International
Organization for Standardization. International standard 19332:2007: oil of
blue chamomile (Chamomilla recutita (L.) Rauschert syn. Matricaria chamomilla auct.). Geneva, Switzerland:
International Organization for Standardization. 2007.
- Aertgeerts P, Albring M, Klaschka F, et al. Vergleichende
Prüfung von Kamillosan®-Creme gegenüber steroidalen (0,25% Hydrocortison, 0,75%
Fluocortinbutylester) und nichtsteroidalen (5% Bufexamac) Externa in der
Erhaltungstherapie von Ekzemerkrankungen. Z
Hautkr. 1985;60(3):270-277.
- Amsterdam
JD, Li Y, Soeller I, Rockwell K, Mao JJ, Shults J. A randomized, double-blind,
placebo-controlled trial of oralMatricaria recutita (chamomile) extract therapy for generalized
anxiety disorder. J Clin Psychopharmacol.2009;29:378-382.
- Amsterdam JD, Shults J, Soeller I, Mao JJ, Rockwell K,
Newberg AB. Chamomile (Matricaria recutita) may
provide antidepressant activity in anxious, depressed humans: an exploratory
study. Alt Ther Health Med. 2012;18(5):44-49.
- Agah S,
Taleb A, Moeini R, Gorji N, Nikbakht H, Soltani-Kermanshahi M. Chamomile
efficacy in patients of the irritable bowel syndrome. Der Pharma Chemica. 2015;7(4):41-45.
- Shabanloei
R, Ahmadi F, Vaez J, et al. Alloporinal, chamomile and normal saline
mouthwashes for the prevention of chemotherapy-induced stomatitis. Journal of Clinical and Diagnostic
Research. 2009;3:1537-1542.
- Tadbir AA, Pourshahidi S, Ebrahimi H, Hajipour Z,
Memarzade MR, Shirazian S. The effect of Matricaria chamomilla(chamomile) extract in
Orabase on minor aphthous stomatitis, a randomized clinical trial. Journal of Herbal Medicine. 2015;5:71-76.
- Seyyedi
S-A, Sanatkhani M, Pakfetrat A, Olyaee P. The therapeutic effects of chamomilla
tincture mouthwash on oral aphthae: a randomized clinical trial. Oral Medicine and Pathology. 2014;6(5):e538-538.
- Shoara R,
Hashempur MH, Ashraf A, Salehi A, Dehshahri S, Habibagahi Z. Efficacy and
safety of topical Matricaria chamomilla L.
(chamomile) oil for knee osteoarthritis: a randomized controlled clinical
trial. Complementary Therapies in
Clinical Practice. 2015;21:181-187.
- Sharifi
F, Simbar M, Mojab F, Majd HA. Comparison of the effects of Matricaria
chamomile (chamomile)
extract and mefenamic acid on the intensity of mastalgia associated with
premenstrual syndrome. Women’s
Health Bull.2014;1(2):e20042.
- Hashempur
MH, Lari ZN, Ghoreishi PS, et al. A pilot randomized double-blind
placebo-controlled trial on topical chamomile (Matricaria chamomilla L.) oil
for severe carpal tunnel syndrome. Complementary
Therapies in Clinical Practice. 2015;21:223-228.
- Charousaei
F, Dabirian A, Mojab F. Using chamomile solution or a 1% topical hydrocortisone
ointment in the management of peristomal skin lesions in colostomy patients:
results of a controlled clinical study. Ostomy
Wound Management. 2011;57(5):28-36.
- Pourabbas
R, Delazar A, Chitsaz MT. The effect of German chamomile mouthwash on dental
plaque and gingival inflammation. Iranian
Journal of Pharmaceutical Research. 2005;2:105-109.
- Howrey
BT, Peek MK, McKee JM, Raji MA, Ottenbacher KJ, Markides KS. Chamomile
consumption and mortality: a prospective study of Mexican origin older adults
[published online April 29, 2015]. The Gerontologist.doi:10.1093/geront/gnv051.
- Riza E,
Linos A, Petralias A, de Martinis L, Duntas L, Linos D. The effect of Greek
herbal tea consumption on thyroid cancer: a case-control study [published
online April 4, 2015]. European
Journal of Public Health.doi:http://dx.doi.org/10.1093/eurpub/ckv063.
- Bundesministerium für Ernährung,
Landwirtschaft und Verbraucherschutz (BMELV). Natürlich gesund: Arzneipflanzen sind ein Markt mit Zukunft. Themendienst Biobasierte Wirtschaft.
2013;4:1-3.
- Beutgen M. 2014: Kräuter- und Früchtetee-Absatz auf hohem Niveau stabil — Der Trend
geht zur Vielfalt. Hamburg City Süd: Wirtschaftsvereinigung Kräuter- und Früchtetee e.V. (WKF). 2015.
Available at: www.wkf.de/. Accessed August 22, 2015.
- Seidler-Lozykowska
K. Chamomile cultivars and their cultivation in Poland. Acta Horticulturae. 2007;749:111-115.
- El-Shrief
LM, Hassan HBA, Hassan MB, Abdel-Fattah HY. An economic study of the Egyptian
exports of major medicinal and aromatic crops. Journal of Applied Sciences Research.
2009;5(12):2171-2178.
- Sallam W.
A market study analysis study on the Egyptian herbs and spices sub-sector.
Cairo, Egypt: Egyptian-German SME Promotion Programme. December 2006.
- Plescher A. Kamilleblüten – ein
pflanzlicher Ausgangsstoff für
hochwertige pharmazeutische Erzeugnisse. In: Gülzower Fachgespräche Band 44: Tagungsband zur 2. Tagung
Arzneipflanzenanbau in Deutschland. Gülzow-Prüzen,
Germany: Fachagentur Nachwachsende Rohstoffe e.V. (FNR). 2014;61-79.
- Meo Carbon Solutions GmbH. Marktanalyse Nachwachsende
Rohstoffe. Schriftenreihe Nachwachsende Rohstoffe, Band 34. Gülzow-Prüzen:
Fachagentur Nachwachsende Rohstoffe e.V. (FNR). 2014. Available at:
http://fnr.de/marktanalyse/marktanalyse.pdf. Accessed August 23, 2015.
- Tetra
Tech ARD. Kosovo new opportunities for agriculture program, fiscal year 2013
annual report. Pristina: Kosovo. USAID. October 2013. Available at:
http://pdf.usaid.gov/pdf_docs/PA00K2QT.pdf. Accessed August 23, 2015.
- Turudija-Živanović S,
Stevanetic S, Ceranić S, Živanović T. Trends in production of raw medicinal and
aromatic plants in Serbia. In: Fifth
International Scientific Agricultural Symposium “Agrosym 2014” Proceedings.
Jahorina: Bosnia and Herzegovina. October 23-26, 2014; 1106-1111.
- Euro
Prima doo website, Novi Sad, Serbia. Available at: www.europrima.rs/. Accessed
August 23, 2015.
- Beier K,
Ehlert D. Methods for evaluation of picking performance of chamomile (Matricaria
recutita L.) harvesters. Part I:
comparison of established methods. Journal
of Applied Research on Medicinal and Aromatic Plants. 2014;1(1):e1-7.
- Beier K,
Ehlert D. Methods for evaluation of picking performance of chamomile (Matricaria
recutita L.) harvesters. Part 2:
Development of new methods. Journal
of Applied Research on Medicinal and Aromatic Plants. 2014;1(2):35-42.
- Ehlert D,
Beier K. Development of picking devices for chamomile harvesters. Journal of Applied Research on Medicinal
and Aromatic Plants. 2014;1(3):73-80.
- Market
Insider. New research for improved chamomile harvesting technology and quality.
Geneva: International Trade Centre. December 22, 2014. Available at:
www.intracen.org/blog/New-research-for-improved-chamomile-harvesting-technology-and-quality/.
Accessed August 24, 2015.
- Brinckmann
JA. Market potential for wild-collected Chinese medicinal and aromatic plants
with sustainability certifications. Geneva, Switzerland: International Trade
Centre. 2015. xv, 140 pages. In press.
|